Literature DB >> 11756989

Selective reactivation of human herpesvirus 6 variant a occurs in critically ill immunocompetent hosts.

Raymund R Razonable1, Cara Fanning, Robert A Brown, Mark J Espy, Antonio Rivero, Jennie Wilson, Walter Kremers, Thomas F Smith, Carlos V Paya.   

Abstract

Reactivation of human beta-herpesviruses (cytomegalovirus [CMV], human herpesvirus [HHV]-6, and HHV-7) in nonimmunocompromised hosts is rare. Because these viruses are susceptible to reactivation by cytokines and stress-related mechanisms, the incidence of their reactivation was investigated among 120 patients during stress related to critical illness and compared with findings among 50 healthy volunteers. Human beta-herpesvirus DNA was found in 65% of critically ill patients (60% men; mean age, 63 years) who required admission to an intensive care unit for medical (40%) or surgical (53%) indications or trauma (7%). HHV-6 reactivation was higher in critically ill patients than in healthy volunteers (54/101 vs. 0/50; P=.001). All patients except 1 were confirmed as HHV-6 variant A (mean virus load, 5066 copies/10(6) peripheral blood leukocytes). The reactivation of HHV-6A did not affect disease severity and outcome. No significant reactivation of HHV-7 or CMV was demonstrated among the critically ill patients. These findings contribute to the less-defined epidemiology of HHV-6A infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756989     DOI: 10.1086/324772

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients.

Authors:  Raymund R Razonable; Carlos V Paya; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 2.  Impact of cytomegalovirus load on host response to sepsis.

Authors:  Thomas Marandu; Michael Dombek; Charles H Cook
Journal:  Med Microbiol Immunol       Date:  2019-04-11       Impact factor: 3.402

3.  Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically Ill Adults.

Authors:  Paula Lopez Roa; Joshua A Hill; Katharine A Kirby; Wendy M Leisenring; Meei-Li Huang; Tracy K Santo; Keith R Jerome; Michael Boeckh; Ajit P Limaye
Journal:  Crit Care Med       Date:  2015-07       Impact factor: 7.598

4.  Efficient identification of inherited chromosomally integrated human herpesvirus 6 using specimen pooling.

Authors:  Joshua A Hill; Ruth HallSedlak; Amalia Magaret; Meei-Li Huang; Danielle M Zerr; Keith R Jerome; Michael Boeckh
Journal:  J Clin Virol       Date:  2016-02-20       Impact factor: 3.168

5.  Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review.

Authors:  Elda Righi; Alessia Carnelutti; Daniele Muser; Francesco Zaja; Elisa Lucchini; Federico Pea; Fernando Di Gregorio; Abass Alavi; Matteo Bassetti
Journal:  J Neurovirol       Date:  2017-08-18       Impact factor: 2.643

6.  High-level human herpesvirus-6 viremia associated with onset of Stevens-Johnson syndrome: report of two cases.

Authors:  Amanda F Peppercorn; Melissa B Miller; David Fitzgerald; David J Weber; Pamela A Groben; Bruce A Cairns
Journal:  J Burn Care Res       Date:  2010 Mar-Apr       Impact factor: 1.845

7.  Impact of human herpes virus 6 in liver transplantation.

Authors:  Raymund R Razonable; Irmeli Lautenschlager
Journal:  World J Hepatol       Date:  2010-09-27

8.  Cytomegalovirus in the intensive care unit: pathogen or passenger?

Authors:  Jeffrey I Cohen
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

Review 9.  Human herpesvirus 6 infections after liver transplantation.

Authors:  Rima Camille Abdel Massih; Raymund R Razonable
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

Review 10.  Cytomegalovirus infection in critically ill patients: a systematic review.

Authors:  Ryosuke Osawa; Nina Singh
Journal:  Crit Care       Date:  2009-05-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.